Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S, a Danish biotechnology company and foreign private issuer filing annual reports on Form 20-F, furnished this Form 6-K for January 2024. The filing reports an announced change to the company’s American Depositary Share (ADS) ratio.
Key financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material change versus the prior period
Effective January 22, 2024, the ADS-to-ordinary-share ratio changed from one ADS representing one ordinary share to one ADS representing ten ordinary shares. This is a 10-for-1 change in the number of ordinary shares represented by each ADS and does not, based on the filing text, provide information about a change in the company’s underlying equity value.
Guidance, outlook, risks, and unusual items
The filing contains no financial guidance, operating outlook, management discussion, new risk disclosures, contingencies, or unusual financial items. The report states that it is incorporated by reference into specified Form S-8, Form F-3, and Form F-1 registration statements, subject to subsequent filings.
Facts investors should verify
- Confirm that the 1-for-10 ADS ratio change became effective on January 22, 2024.
- Verify the resulting ADS trading price, share count presentation, and any related depositary or broker adjustments.
- Review the furnished January 22, 2024 press release, filed as Exhibit 99.1, for implementation details.
- Consult the company’s financial filings separately for performance, cash runway, financing needs, and other investment risks, which are not addressed in this Form 6-K.